A prospective study of infections in lung cancer patients admitted to the hospital.
OBJECTIVE
To determine the type of infections occurring in hospitalized patients with lung cancer.


METHODS
Prospective cohort study.


METHODS
Department of internal medicine in a cancer hospital.


METHODS
All patients with lung cancer who were hospitalized for any cause and who acquired infections at the time of admission or during the hospital stay between January 1997 and February 2001.


METHODS
None.


RESULTS
Two hundred seventy-five patients with lung cancer had 435 episodes of fever and/or microbiologically or otherwise documented infection. Two hundred eighteen patients (79.3%) presented with non-small cell lung carcinoma, while 49 patients (17.8%) had small cell lung cancer. The majority of the infections occurred in the tracheobronchial tree (56%). There were 38 episodes of bacteremia or fungemia, and the primary site of infection was identified in 18 cases (47%). Microbiologically documented infections accounted for 61% of the infectious episodes, and included a total of 312 microorganisms. The most frequent pathogens were Gram-negative bacteria (64%), followed by Gram-positive bacteria (25%) and fungi (8%). The predominant Gram-negative bacteria were Haemophilus influenzae and Moraxella catarrhalis. Staphylococcus aureus, Streptococcus pneumoniae, coagulase-negative staphylococci, and Enterococcus faecalis essentially represented the Gram-positive bacteria. No multiresistant bacteria were observed. Bacteria were susceptible to most of the antibiotics classically administered for their treatment.


CONCLUSIONS
The predominant site of infection in patients with lung cancer is the tracheobronchial tree, with S pneumoniae, S aureus, H influenzae, Escherichia coli, Pseudomonas aeruginosa, and M catarrhalis as the principal pathogens.
Berghmans
Thierry
T
Service de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium. thierry.berghmans@bordet.be
Sculier
Jean-Paul
JP
Klastersky
Jean
J
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000453:epidemiology; D001424:Bacterial Infections / Q000150:complications / Q000453:epidemiology*; D001982:Bronchial Diseases / Q000150:complications / Q000453:epidemiology / Q000382:microbiology; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications*; D018288:Carcinoma, Small Cell / Q000150:complications*; D015331:Cohort Studies; D006760:Hospitalization; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D009181:Mycoses / Q000150:complications / Q000453:epidemiology; D011446:Prospective Studies; D014133:Tracheal Diseases / Q000150:complications / Q000453:epidemiology / Q000382:microbiology
D000900:Anti-Bacterial Agents